April Kennedy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
April Kennedy has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Iris Cohn
Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
3 shared publications Akanchha Kesari
Illumina Inc San Diego California USA
1 shared publicationAlassane Baneye Maiga
Department of Medicine University of Sciences, Techniques and Technologies of Bamako Bamako Mali
1 shared publicationAleixo M Muise
SickKids IBD Centre, Division of Gastroenterology, Hepatology & Nutrition, The Hospital for Sick Children , Toronto, Ontario
1 shared publication- Amanda R. Clause
Department of Neurology, Washington University School of Medicine, St. Louis, MO
1 shared publication Amanda Ricciuto
SickKids IBD Centre, Division of Gastroenterology, Hepatology & Nutrition, The Hospital for Sick Children , Toronto, Ontario
1 shared publication
Latest Publications
- Open Access
- 8 August 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (8) , 1170
Pharmacogenetic Testing of Children and Adolescents with Mental Health Conditions: Real-World Experiences
Background/Objectives: Medication discontinuation attributable to adverse drug reactions (ADRs) and/or inefficacy remains a concern of psychotropic medications among children and adolescents. Pharmacogenetic (PGx) testing has been proposed to individualize treatment, although its utility remains uncertain. We retrospectively evaluated whether PGx testing of two key metabolism genes (i.e., CYP2C19 and CYP2D6) explains reported episodes of ADRs and treatment inefficacy experienced by children and adolescents with diverse mental health conditions. Methods: PGx testing of CYP2C19 and CYP2D6 was conducted for 100 participants before, during, or after the use of psychotropic medication(s) that have clinical practice guidelines supporting PGx-guided dosing. The theoretical impact on medication dosing was reviewed in the context of clinical guidelines. We then evaluated whether the PGx-inferred metabolizer phenotype was consistent with reported ADR and/or treatment inefficacy. Results: If PGx testing had been performed before the start of treatment, 43% (35/82) of participants would have been recommended dose adjustments or alternative therapy of at least one medication. PGx test results corroborated 8% (6/76) of ADR events and 3% (2/61) of inefficacies. However, no single participant had all prior reported ADRs or inefficacies explained by the results of CYP2C19 nor CYP2D6 testing. Conclusions: Reactive testing of CYP2C19 and CYP2D6 provided limited insight into isolated incidents of psychotropic medication intolerance in this population. No individual’s PGx test results explained all episodes of ADR or suboptimal response. Variation in drug metabolism genes alone does not provide an explanation for multiple episodes of inefficacy or adverse reaction. In the setting of child and adolescent psychiatry, PGx testing is best suited for preemptive use to complement clinical decision making.
- 8 August 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (8) , 1170
Open AccessPharmacogenetic Testing of Children and Adolescents with Mental Health Conditions: Real-World Experiences
Background/Objectives: Medication discontinuation attributable to adverse drug reactions (ADRs) and/or inefficacy remains a concern of psychotropic medications among children and adolescents. Pharmacogenetic (PGx) testing has been proposed to individualize treatment, although its utility remains uncertain. We retrospectively evaluated whether PGx testing of two key metabolism genes (i.e., CYP2C19 and CYP2D6) explains reported episodes of ADRs and treatment inefficacy experienced by children and adolescents with diverse mental health conditions. Methods: PGx testing of CYP2C19 and CYP2D6 was conducted for 100 participants before, during, or after the use of psychotropic medication(s) that have clinical practice guidelines supporting PGx-guided dosing. The theoretical impact on medication dosing was reviewed in the context of clinical guidelines. We then evaluated whether the PGx-inferred metabolizer phenotype was consistent with reported ADR and/or treatment inefficacy. Results: If PGx testing had been performed before the start of treatment, 43% (35/82) of participants would have been recommended dose adjustments or alternative therapy of at least one medication. PGx test results corroborated 8% (6/76) of ADR events and 3% (2/61) of inefficacies. However, no single participant had all prior reported ADRs or inefficacies explained by the results of CYP2C19 nor CYP2D6 testing. Conclusions: Reactive testing of CYP2C19 and CYP2D6 provided limited insight into isolated incidents of psychotropic medication intolerance in this population. No individual’s PGx test results explained all episodes of ADR or suboptimal response. Variation in drug metabolism genes alone does not provide an explanation for multiple episodes of inefficacy or adverse reaction. In the setting of child and adolescent psychiatry, PGx testing is best suited for preemptive use to complement clinical decision making.
- Open Access
- 30 August 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (9) , 2268-2276
Expert panel curation of 31 genes in relation to limb girdle muscular dystrophy
Objective: Limb girdle muscular dystrophies (LGMDs) are a group of genetically heterogeneous autosomal conditions with some degree of phenotypic homogeneity. LGMD is defined as having onset >2 years of age with progressive proximal weakness, elevated serum creatine kinase levels and dystrophic features on muscle biopsy. Advances in massively parallel sequencing have led to a surge in genes linked to LGMD.Methods: The ClinGen Muscular Dystrophies and Myopathies gene curation expert panel (MDM GCEP, formerly Limb Girdle Muscular Dystrophy GCEP) convened to evaluate the strength of evidence supporting gene–disease relationships (GDR) using the ClinGen gene–disease clinical validity framework to evaluate 31 genes implicated in LGMD.Results: The GDR was exclusively LGMD for 17 genes, whereas an additional 14 genes were related to a broader phenotype encompassing congenital weakness. Four genes (CAPN3, COL6A1, COL6A2, and COL6A3) were split into two separate disease entities, based on each displaying both dominant and recessive inheritance patterns, resulting in curation of 35 GDRs. Of these, 30 (86%) were classified as definitive, 4 (11%) as moderate, and 1 (3%) as limited. Two genes, POMGNT1 and DAG1, though definitively related to myopathy, currently have insufficient evidence to support a relationship specifically with LGMD.Interpretation: The expert‐reviewed assertions on the clinical validity of genes implicated in LGMDs form an invaluable resource for clinicians and molecular geneticists. We encourage the global neuromuscular community to publish case‐level data that help clarify disputed or novel LGMD associations.
- 30 August 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (9) , 2268-2276
Open AccessExpert panel curation of 31 genes in relation to limb girdle muscular dystrophy
Objective: Limb girdle muscular dystrophies (LGMDs) are a group of genetically heterogeneous autosomal conditions with some degree of phenotypic homogeneity. LGMD is defined as having onset >2 years of age with progressive proximal weakness, elevated serum creatine kinase levels and dystrophic features on muscle biopsy. Advances in massively parallel sequencing have led to a surge in genes linked to LGMD.Methods: The ClinGen Muscular Dystrophies and Myopathies gene curation expert panel (MDM GCEP, formerly Limb Girdle Muscular Dystrophy GCEP) convened to evaluate the strength of evidence supporting gene–disease relationships (GDR) using the ClinGen gene–disease clinical validity framework to evaluate 31 genes implicated in LGMD.Results: The GDR was exclusively LGMD for 17 genes, whereas an additional 14 genes were related to a broader phenotype encompassing congenital weakness. Four genes (CAPN3, COL6A1, COL6A2, and COL6A3) were split into two separate disease entities, based on each displaying both dominant and recessive inheritance patterns, resulting in curation of 35 GDRs. Of these, 30 (86%) were classified as definitive, 4 (11%) as moderate, and 1 (3%) as limited. Two genes, POMGNT1 and DAG1, though definitively related to myopathy, currently have insufficient evidence to support a relationship specifically with LGMD.Interpretation: The expert‐reviewed assertions on the clinical validity of genes implicated in LGMDs form an invaluable resource for clinicians and molecular geneticists. We encourage the global neuromuscular community to publish case‐level data that help clarify disputed or novel LGMD associations.
- Open Access
- 24 May 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 30 (12) , 2418-2427
Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients
Background: Patients with inflammatory bowel disease (IBD) exhibit considerable interindividual variability in medication response, highlighting the need for precision medicine approaches to optimize and tailor treatment. Pharmacogenetics (PGx) offers the ability to individualize dosing by examining genetic factors underlying the metabolism of medications such as thiopurines. Pharmacogenetic testing can identify individuals who may be at risk for thiopurine dose-dependent adverse reactions including myelosuppression. We aimed to evaluate PGx variation in genes supported by clinical guidelines that inform dosing of thiopurines and characterize differences in the distribution of actionable PGx variation among diverse ancestral groups. Methods: Pharmacogenetic variation in TPMT and NUDT15 was captured by genome-wide genotyping of 1083 pediatric IBD patients from a diverse Canadian cohort. Genetic ancestry was inferred using principal component analysis. The proportion of PGx variation and associated metabolizer status phenotypes was compared across 5 genetic ancestral groups within the cohort (Admixed American, African, East Asian, European, and South Asian) and to prior global estimates from corresponding populations. Results: Collectively, 11% of the cohort was categorized as intermediate or poor metabolizers of thiopurines, which would warrant a significant dose reduction or selection of alternate therapy. Clinically actionable variation in TPMT was more prevalent in participants of European and Admixed American/Latino ancestry (8.7% and 7.5%, respectively), whereas variation in NUDT15 was more prevalent in participants of East Asian and Admixed American/Latino ancestry (16% and 15% respectively). Conclusions: These findings demonstrate the considerable interpopulation variability in PGx variation underlying thiopurine metabolism, which should be factored into testing diverse patient populations.
- 24 May 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 30 (12) , 2418-2427
Open AccessLandscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients
Background: Patients with inflammatory bowel disease (IBD) exhibit considerable interindividual variability in medication response, highlighting the need for precision medicine approaches to optimize and tailor treatment. Pharmacogenetics (PGx) offers the ability to individualize dosing by examining genetic factors underlying the metabolism of medications such as thiopurines. Pharmacogenetic testing can identify individuals who may be at risk for thiopurine dose-dependent adverse reactions including myelosuppression. We aimed to evaluate PGx variation in genes supported by clinical guidelines that inform dosing of thiopurines and characterize differences in the distribution of actionable PGx variation among diverse ancestral groups. Methods: Pharmacogenetic variation in TPMT and NUDT15 was captured by genome-wide genotyping of 1083 pediatric IBD patients from a diverse Canadian cohort. Genetic ancestry was inferred using principal component analysis. The proportion of PGx variation and associated metabolizer status phenotypes was compared across 5 genetic ancestral groups within the cohort (Admixed American, African, East Asian, European, and South Asian) and to prior global estimates from corresponding populations. Results: Collectively, 11% of the cohort was categorized as intermediate or poor metabolizers of thiopurines, which would warrant a significant dose reduction or selection of alternate therapy. Clinically actionable variation in TPMT was more prevalent in participants of European and Admixed American/Latino ancestry (8.7% and 7.5%, respectively), whereas variation in NUDT15 was more prevalent in participants of East Asian and Admixed American/Latino ancestry (16% and 15% respectively). Conclusions: These findings demonstrate the considerable interpopulation variability in PGx variation underlying thiopurine metabolism, which should be factored into testing diverse patient populations.
- Open Access
- 22 February 2024
- Published by Springer Nature in npj Genomic Medicine
- Vol. 9 (1) , 1-4
A call for increased inclusivity and global representation in pharmacogenetic testing
Commercial pharmacogenetic testing panels capture a fraction of the genetic variation underlying medication metabolism and predisposition to adverse reactions. In this study we compared variation in six pharmacogenes detected by whole genome sequencing (WGS) to a targeted commercial panel in a cohort of 308 individuals with family history of pediatric heart disease. In 1% of the cohort, WGS identified rare variants that altered the interpretation of metabolizer status and would thus prevent potential errors in gene-based dosing.
- 22 February 2024
- Published by Springer Nature in npj Genomic Medicine
- Vol. 9 (1) , 1-4
Open AccessA call for increased inclusivity and global representation in pharmacogenetic testing
Commercial pharmacogenetic testing panels capture a fraction of the genetic variation underlying medication metabolism and predisposition to adverse reactions. In this study we compared variation in six pharmacogenes detected by whole genome sequencing (WGS) to a targeted commercial panel in a cohort of 308 individuals with family history of pediatric heart disease. In 1% of the cohort, WGS identified rare variants that altered the interpretation of metabolizer status and would thus prevent potential errors in gene-based dosing.